Enliven Therapeutics, Inc. Quarterly Income Tax Expense (Benefit) in USD for Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Enliven Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate for Q2 2024.
  • Enliven Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $232K.
  • Enliven Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $0.000.
Income Tax Expense (Benefit), Quarterly (USD)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $232K Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.